Close Menu

You may find more results for this query on our sister sites: GenomeWeb and 360Dx.

Home › Business, Policy & Funding › Policy & Legislation › UK's NICE Backs Tagrisso for First-, Second-Line EGFR-Positive Lung Cancer

UK's NICE Backs Tagrisso for First-, Second-Line EGFR-Positive Lung Cancer

Sep 11, 2020
|
staff reporter

NEW YORK – The UK's National Institute for Health and Care Excellence on Friday published a draft decision saying that it would recommend osimertinib (AstraZeneca's Tagrisso) for routine use in the National Health Service for first-line treatment of advanced, EGFR mutation-positive non-small-cell lung cancer patients, and second-line treatment of locally advanced or metastatic, EGFR mutation-positive NSCLC patients who have the T790m resistance mutation.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Feb
11
Featured Webinar

Virtual Molecular Tumor Board Series: HRD and DNA Damage Repair

Sponsored by
Foundation Medicine

In this session, the first in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified biomarkers related to homologous recombination deficiency and DNA damage repair.

Feb
25
Featured Webinar

Virtual Molecular Tumor Board Series: Common Driver Mutations in ‘Off-Label’ Tumor Types

Sponsored by
Foundation Medicine

In this session, the second in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review cases in which patient genomic profiles exhibit common driver mutations in tumor types considered “off label” for targeted therapies associated with those mutations.

Mar
11
Featured Webinar

Virtual Molecular Tumor Board Series: Gene Fusions as Druggable Targets

Sponsored by
Foundation Medicine

In this session, the third in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified gene fusions that may or may not serve as druggable targets.

Mar
25
Featured Webinar

Virtual Molecular Tumor Board Series: What to Do with a ‘Negative’ Molecular Panel Case

Sponsored by
Foundation Medicine

In this session, the fourth in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling identified no clear molecular markers to help guide personalized therapy.

What's Popular?

In Cancer

  1. FDA Approves Daiichi Sankyo, AstraZeneca's Enhertu for Gastric, Gastroesophageal Junction Cancer

  2. JP Morgan Healthcare, Day 3 and 4: ImmunoGen, Precigen, Autolus, Exact Sciences, Jounce, and More

  3. UK's NICE Recommends Gilead's CAR T-cell Therapy Tecartus for Mantle Cell Lymphoma

  4. Predictive Oncology Prices $2.2M Direct Offering

  5. CMS Finalizes Blood-Based Colon Cancer Screening NCD with Non-Coverage for Epi ProColon

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.